The WHO guidelines recommend treating people with DS-TB with a 6-month regimen composed of four first-line TB medicines: isoniazid, rifampicin, pyrazinamide and ethambutol (1). The regimen is a combination of those four drugs (i.e. HRZE) for 2 months followed by isoniazid and rifampicin (i.e. HR) for 4 months, administered daily.

• Standard anti-tuberculosis regimen of 2EHRZ/4HR should be used in the treatment of pulmonary tuberculosis (PTB). • Only daily anti-tuberculosis regimen should be used throughout the

Since 2010, the WHO guidelines have recommended treating persons with DS-TB with a 6-month regimen composed of four first line TB medicines – isoniazid, rifampicin, ethambutol and pyrazinamide – where rifampicin is used for 6 months (2HRZE/4HR).

Key considerations in DS-TB treatment. 3. Treatment of DS-TB using the 6-month regimen. 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen. 5. Treatment of DS-TB using the 4-month 2HRZ (E)/2HR regimen. 6. Treatment of DS-TB in People with HIV. 7. Treatment of extrapulmonary TB. 8. Treatment of DS-TB in special situations. 9.

In 2021, a 4-month regimen comprising INH, pyrazinamide (PZA, Z), rifapentine (P) and moxifloxacin (Mfx) was shown to be non-inferior to the standard 6-month DS-TB regimen. 14 This shorter regimen could potentially signify a paradigm shift in the management of DS-TB treatment.

Patients with a large bacillary load (sputum smear-positive pulmonary TB and many HIV-infected patients with smear-negative pulmonary TB) have an increased risk of selecting resistant bacilli. Short-course chemotherapy regimens with four drugs (HRZE) in the initial phase reduce this risk.

The effectiveness of 4-month fluoroquinolone-containing regimens when compared to the standard 6-month treatment regimen of 2HRZE/4HR in patients with drug-susceptible pulmonary TB disease. 1.2.

2HRZE/4HR = initial phase of 2 months of isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E), followed by continuation phase of 4 months of isoniazid and rifampicin; ATS = American Thoracic Society; CDC = Centers for Disease Control and Prevention; ECDC = European Centre for Disease Prevention and Control; ERS = European ...

In children and adolescents between 3 months and 16 years of age with non-severe TB (without suspicion or evidence of MDR/RR-TB), a 4-month treatment regimen (2HRZ(E)/2HR) should be used. (Strongrecommendation, moderate certainty of evidence)SHINE: Shorter Treatment for Minimal Tuberculosis in Children.

Dec 4, 2024 · Presently, a 6-month regimen consisting of 2 months of daily (intensive regimen) EHRZ (2EHRZ) followed by 4 months of daily (maintenance regimen) HR (4HR) is the recommended and preferred treatment for patients with newly diagnosed PTB.